ARM Releases Second-Quarter Report on Regenerative Medicines Sector

The Alliance for Regenerative Medicine’s (ARM) report highlights major trends and metrics from the 2018 second quarter in the regenerative medicines sector.
Aug 09, 2018
By Pharmaceutical Technology Editors

On Aug. 8, 2018, The Alliance for Regenerative Medicine (ARM) released its most recent quarterly data report that examines trends and metrics in cell therapy, gene therapy, tissue engineering, and the broader global regenerative medicine sector in the second quarter (Q2) and first half of 2018.

With information provided by Informa, ARM’s data partner, the report details industry-specific statistics compiled from more than 875 cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical-trial information, key clinical-data events, and current legislative and regulatory priorities.

The report also features commentary from ARM’s recent webinar on FDA’s regenerative medicine advanced therapy (RMAT) designation, cohosted with Informa. The commentary includes insights from Michael Werner, ARM co-founder and senior policy counsel; Kevin Healy, global regulatory lead at Roivant Sciences, representing Enzyvant Therapeutics; Gil Van Bokkelen, CEO of Athersys; and Tim Miller, president and chief scientific officer at Abeona Therapeutics. The report also includes a brief comparison of the RMAT designation and the breakthrough therapy designation, provided by Amanda Micklus, principal analyst at Pharma Intelligence at Informa.

“There has been a tremendous amount of forward momentum during the first half of this year, both clinically and commercially,” said Janet Lynch Lambert, ARM’s CEO, in the organization’s press release. “We’re excited for the continued growth of the regenerative medicine sector, and what it means for patients worldwide.”

Report highlights

Highlighted findings from the Q2 2018 data report include:

  • Companies that are globally active in gene and cellular therapies and other regenerative medicines raised more than $4.1 billion in the second quarter of 2018, a 164% increase from Q2 2017. The report also includes financial data broken out by technology type and financing type.
  • There were 977 clinical trials underway worldwide at the close of the Q2 2018, with oncology accounting for more than 54% and cardiovascular disorders accounting for nearly 10%. The report also includes figures on clinical trials by phase and indication as well as by technology type.

ARM states that it plans to continue tracking sector performance, key financial information, clinical trial numbers, and clinical data events and update this information in new reports to be released after the close of each quarter.

Source: Alliance for Regenerative Medicine

native1_300x100
lorem ipsum